Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.

Authors

Yaping Sun, Xiaolei Li, Liwu Xu

Published in

Endocrine. Volume 91. Issue 1. Jul 13, 2026. Epub Jul 13, 2026.

Abstract

To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM).
In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart. The primary endpoint was the proportion of patients achieving high-quality glycemic control [time in range(TIR) > 70%, coefficient of variation (CV) < 36%, and no hypoglycemia]. Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices.
Compared with controls, the IDegLira group showed higher TIR (84.03% vs. 74.67%, P = 0.007) and lower time above range (TBR) (P = 0.005). Glycemic variability indices, including mean glucose(MG) (8.26 vs. 9.74 mmol/L), were significantly improved (all P ≤ 0.003). The IDegLira group required less insulin (37.95 vs. 41.59 U/d, P = 0.03), achieved glycemic targets faster (3.1 vs. 5.0 days, P < 0.001), and had a higher rate of high-quality glycemic control (65.1% vs. 36.5%, P = 0.001). Short-term reductions in insulin resistance and improvements in β-cell function indices were also observed (all P ≤ 0.001).
IDegLira combined with insulin aspart provides superior short-term glycemic control compared with insulin glargine plus insulin aspart in overweight or obese patients with T2DM, with improved glycemic stability, reduced insulin requirements, faster target attainment, and favorable short-term metabolic changes.

PMID:
42439957
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.